Replies to post #763154 on NorthWest Biotherapeutics Inc (NWBO)

[alphapuppy]

The main point being, that this therapy may be useful for a larger number of people when you count both newly diagnosed and recurrent patients. So I'm hoping we get an indication with our Upcoming approval to treat both newly diagnosed and or recurrent patients. And I think we will. The reason is the recurrent Patients have absolutely no standard of care and need this therapy profoundly.. There is no standard of care for recurrent GBM.

[Hopeforthefuture3]

alphpuppy, if you go by the Jama Oncology paper looking at the EAC the median survival for recurrent GBM is 7.8 months. Survival at various time periods is shown as:
12 months 30.8%
18 months 15.9%
24 months 9.6%
30 months 5.1%
I agree they may as well try dcvax as little else seems to help but imo there is not a very large group of recurrent as compared to newly diagnosed that will use the treatment, perhaps at best an equal number of recurrent as newly diagnosed. The coworker I spoke of refused a second surgery as he suffered side effects from the first surgery - at the time I had thought he might benefit from dcvax but it has taken much longer to get any approval